Topics

Articles

The acquisition, the parties say, will benefit pharma and biotech in the clinical and commercial stages. 

Myonex Finalizes Creapharm Deal

Collaboration will be oncology based—centered around allogeneic CAR-T cell therapy product candidates—and will provide Poseida with up to $550 million if certain milestones are met. 

Astellas, Poseida Therapeutics Ink Allogeneic Cell Therapy Agreement

Per the US strategic partnership agreement, the adalimumab high-concentration interchangeable biosimilar will be distributed under the Quallent Pharmaceuticals private label.

Teva and Alvotech Further Strengthen Their Relationship, Reach Biosimilar Commercialization Deal

Study explores how the Inflation Reduction Act’s Drug Price Negotiation Program and its maximum fair prices impact incentives for investments in post-approval activity.

A Look at the Effects of the Inflation Reduction Act 

The merger exponentially grows ONO’s oncology pipeline.

ONO Pharmaceutical Solidifies $2.4 Billion Acquisition of Deciphera

The complex will research solutions for manufacturing antibodies, mRNA applications, and more. 

Merck KGaA Financially Commits $322 Million Toward Research Center

The company adds a top-10 CDMO to its portfolio in the process, while also expanding its commitment to the pharma industry. 

Kühne Holding Inks Deal for Aenova 

The deal further grows the Big Pharma company’s US production capabilities, especially when it comes to global parenteral products.

Eli Lilly Purchases Nexus Pharmaceutical Injectables Manufacturing Plant

Deal gives Incyte access to Escient’s pipeline of oral MRGPR antagonists, including EP262 and EP547. 

Incyte Corporation Inks Deal to Acquire Escient Pharmaceuticals for $750 Million 

Company also purchased equipment for 12 good manufacturing practice clean rooms.

Business and Finance